Global Information
회사소개 | 문의 | 위시리스트

폐동맥 고혈압(PAH) 시장 분석과 예측(2014-2025년) : 프로스타사이클린 및 아날로그, SGC 자극제, ERA, 포스포디에스테라제 5 저해제

Pulmonary Arterial Hypertension (PAH) Market, By Drug Class (Prostacyclin and Analogs, SGC Stimulators, ERA and Phosphodiesterase-5) and Geography - Analysis, Share, Trends, Size, & Forecast From 2014 - 2025

리서치사 AnalystView Market Insights
발행일 2018년 07월 상품 코드 737890
페이지 정보 영문 108 Pages
가격
US $ 3,250 ₩ 3,970,000 PDF by E-mail (Single User Licence) help
1명만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 4,650 ₩ 5,680,000 PDF by E-mail (5 User Licence) help
동일 사업장 내 5명까지 이용할 수 있는 라이선스입니다. 인쇄 횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,650 ₩ 6,902,000 PDF by E-mail (Enterprise User Licence) help
동일 기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 및 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다.
자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



폐동맥 고혈압(PAH) 시장 분석과 예측(2014-2025년) : 프로스타사이클린 및 아날로그, SGC 자극제, ERA, 포스포디에스테라제 5 저해제 Pulmonary Arterial Hypertension (PAH) Market, By Drug Class (Prostacyclin and Analogs, SGC Stimulators, ERA and Phosphodiesterase-5) and Geography - Analysis, Share, Trends, Size, & Forecast From 2014 - 2025
발행일 : 2018년 07월 페이지 정보 : 영문 108 Pages

폐동맥 고혈압(PAH) 시장은 정부의 희귀질병용 의약품 개발 이니셔티브와 질환 인지도 상승, 충분히 계획된 상환구조 등의 요인에 의해 촉진되고 있습니다. 한편 블록버스터의 특허 만료가 새로운 성장을 억제하고 있습니다. 2017년 세계 시장 규모는 53억 8,000만 달러에 이른 것으로 추정됩니다.

세계의 폐동맥 고혈압(PAH: Pulmonary Arterial Hypertension) 시장을 조사했으며, 시장 정의와 개요, 시장 성장 영향요인, 시장 기회, 산업 동향, 관련 규제, 약제 클래스 및 지역별 동향, 시장 규모 추이와 예측, 경쟁 환경과 시장 점유율, 주요 기업 개요 등을 정리했습니다.

제1장 폐동맥 고혈압(PAH) : 시장 개요

제2장 주요 요약

제3장 폐동맥 고혈압(PAH) : 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 향후 동향

제4장 폐동맥 고혈압(PAH) : 산업 분석

  • Porter's Five Forces 분석
  • 시장의 매력 분석
  • 규제 프레임워크 분석

제5장 폐동맥 고혈압(PAH) : 시장 환경

  • 시장 점유율 분석

제6장 폐동맥 고혈압(PAH) 시장 분석과 예측 : 약제 클래스별

  • 개요
  • 프로스타사이클린 및 아날로그
    • 개요
    • 시장 분석, 예측, 전년대비 성장률
  • 가용성 구아닐산 고리화효소(SGC) 자극제
    • 개요
    • 시장 분석, 예측, 전년대비 성장률
  • 엔도텔린 수용체 길항제(ERA)
    • 개요
    • 시장 분석, 예측, 전년대비 성장률
  • 포스포디에스테라제 5 저해제
    • 개요
    • 시장 분석, 예측, 전년대비 성장률

제7장 폐동맥 고혈압(PAH) 시장 분석과 예측 : 지역별

  • 서론
  • 북미
    • 미국
    • 캐나다
      • 개요
      • 시장 분석, 예측, 전년대비 성장률
  • 유럽
    • 프랑스
    • 독일
    • 기타
      • 개요
      • 시장 분석, 예측, 전년대비 성장률
  • 아시아태평양
    • 중국
    • 인도
    • 기타
      • 개요
      • 시장 분석, 예측, 전년대비 성장률
  • 기타 지역
    • 라틴아메리카
    • 중동 및 아프리카
      • 개요
      • 시장 분석, 예측, 전년대비 성장률

제8장 주요 벤더 분석

  • Pfizer, Inc.
  • GlaxoSmithKline
  • Novartis
  • Bayer
  • Merck

제9장 애널리스트의 전방위적 견해

제10장 부록

LSH 18.11.16

List of Tables

  • Table 1 List of Acronyms
  • Table 2 Key Market Facts, 2014 - 2025
  • Table 3 Market Drivers: Impact Analysis
  • Table 4 Market Restraint: Impact Analysis
  • Table 5 Market Opportunity: Impact Analysis
  • Table 6 PEST Analysis
  • Table 7 Porter's Five Forces Analysis
  • Table 8 Company Market Share Analysis
  • Table 9 Global Pulmonary Arterial Hypertension Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • Table 10 Pulmonary Arterial Hypertension Market, by Drug Class, 2014 - 2025 (USD Billion)
  • Table 11 Pulmonary Arterial Hypertension Market, by Geography, 2014 - 2025 (USD Billion)
  • Table 12 North America Pulmonary Arterial Hypertension Market, 2014 - 2025 (USD Billion)
  • Table 13 U.S. Pulmonary Arterial Hypertension Market, 2014 - 2025 (USD Billion)
  • Table 14 Canada Pulmonary Arterial Hypertension Market, 2014 - 2025 (USD Billion)
  • Table 15 Europe Pulmonary Arterial Hypertension Market, 2014 - 2025 (USD Billion)
  • Table 16 France Pulmonary Arterial Hypertension Market, 2014 - 2025 (USD Billion)
  • Table 17 Germany Pulmonary Arterial Hypertension Market, 2014 - 2025 (USD Billion)
  • Table 18 Asia Pacific Pulmonary Arterial Hypertension Market, 2014 - 2025 (USD Billion)
  • Table 19 China Pulmonary Arterial Hypertension Market, 2014 - 2025 (USD Billion)
  • Table 20 India Pulmonary Arterial Hypertension Market, 2014 - 2025 (USD Billion)
  • Table 21 Latin America Pulmonary Arterial Hypertension Market, 2014 - 2025 (USD Billion)
  • Table 22 MEA Pulmonary Arterial Hypertension Market, 2014 - 2025 (USD Billion)

List of Figures

  • Figure 1 Research Methodology
  • Figure 2 Research Process Flow Chart
  • Figure 3 Comparative Analysis, by Geography, 2016-2025 (Value %)
  • Figure 4 Regulatory Framework Analysis
  • Figure 5 Pulmonary Arterial Hypertension Market, by Drug Class, 2014 - 2025 (USD Billion)
  • Figure 6 Pulmonary Arterial Hypertension Market, by Geography, 2014 - 2025 (USD Billion)

Report Hightlights

The pulmonary arterial hypertension (PAH) market is estimated to represent a global market of USD 5.38 billion by 2017 with growth rate of 5.6%.

Market Dynamics

According to the World Health Organization (WHO), pulmonary arterial hypertension is a debilitating condition, characterized by the elevated pulmonary vascular resistance and pulmonary arterial pressure. The condition may lead to the failure of right ventricular or patient's death. PAH can be hereditable, idiopathic, or associated with conditions such as congenital heart disease, connective tissue disease, hypertension, and HIV infection. PAH is categorized under rate disease as the prevalence of this disorder is very low, with an estimated prevalence around 15 to 50 cases per million population. However, the prevalence of this disorder is increasing during the past few years owing to the risk factors such as smoking, tobacco consumption, sedentary lifestyle, and other idiopathic conditions.

The market for Pulmonary Arterial Hypertension is primarily driven by the favourable government initiatives for the development of orphan drugs. The government provides benefits in terms of enhanced patent protection term, tax incentives etc. Rare Disease Act 2002 and The Orphan Drug Act (ODA) 1983 are the two important acts which facilitate the distribution and ethical usage of orphan therapeutics. For instance, The ODA facilitates tax credits up to 50.0% of overall research cost, protocol assistance, waiver in U.S. FDA fees and clinical tax incentives. This fact would, in turn, encourage key players to invest in this industry, augmenting the market growth to great extent.

Furthermore, growing awareness coupled with a well-planned reimbursement structure resulted in superlative diagnosis rate for PAH conditions across the globe, driving the industry growth. However, patent expiry of blockbuster therapeutics pulls back the industry growth to some extent. For instance, drugs such as Uptravi (2023), Orenitram (2024), and Opsumit are expired in near future. Additionally, this condition is often not diagnosed in a timely manner owing to its symptoms are subtle, and is confused with many other disease conditions. This fact would, in turn, further reduce the number of patients undergoing PAH treatment, hampering the market growth to some extent.

Drug Class Takeaway

In terms of drug class, the industry is categorized as Prostacyclin and Analogs, Soluble Guanylyl Cyclase (SGC) Stimulators, Endothelin receptor antagonist (ERA) and Phosphodiesterase-5. An ERA dominated the market with a substantial share of over 40% throughout the study period. On another hand, drugs targeting the prostacyclin pathway reported global sales of over USD 2.3 billion in 2017. Iloprost (Ventavis from Actelion), Epoprostenol (Veletri from Actelion and Flolan from GSK), Treprostinil (Tyvaso, Remodulin, and Orenitram from United Therapeutics) are some of the prostacyclin analogs approved by the U.S. FDA for the treatment of PAH. SGC stimulators are the lowest revenue generating drug class owing to the availability of other effective therapeutics.

Global Pulmonary Arterial Hypertension Market, by Drug Class, 2017 vs 2025

Regional Takeaway

Geographically, the industry is categorized into North America, Europe, Asia Pacific and Rest of the World. Developed regions such as North America and Europe accounted for the highest share of the global market.

Key Vendor Takeaway

Companies such as Pfizer, Inc., GlaxoSmithKline, Novartis, Bayer, and Merck are some of the prominent participants in the global Pulmonary Arterial Hypertension market. Apart of it, the presence of small players is noticeable too. For instance, Actelion Pharmaceuticals is developing a Macitentan drug for pediatric PAH. The company has initiated phase III (titled as "Tomorrow") study which will evaluate the effect of macitentan on children with PAH. Also, in October 2015, Gilead Sciences, Inc.'s new combination treatment of Tadalafil and Letairis is approved by the U.S. FDA. Such facts will further help key players to enhance their market presence.

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year - 2014 & 2016

Base Year - 2017

Estimated Year - 2018

Projected Year - 2025

TARGET AUDIENCE

Traders, Distributors, and Suppliers

Manufacturers

Hospitals

Government and Regional Agencies and Research Organizations

Consultants

Distributors

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

MARKET, BY DRUG CLASS

Prostacyclin and Analogs

Soluble Guanylyl Cyclase (SGC) Stimulators

Endothelin receptor antagonist (ERA)

Phosphodiesterase-5

MARKET, BY REGION

North America

U.S.

Canada

Europe

Germany

France

Rest of Europe

Asia Pacific

India

China

Rest of APAC

Rest of the World

Middle East and Africa

Latin America

TABLE OF CONTENTS

1. PULMONARY ARTERIAL HYPERTENSION MARKET OVERVIEW

  • 1.1. Study Scope
  • 1.2. Assumption and Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Key Market Facts
  • 2.2. Geographical Scenario
  • 2.3. Companies in the Market

3. PULMONARY ARTERIAL HYPERTENSION KEY MARKET TRENDS

  • 3.1. Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Future Trends

4. PULMONARY ARTERIAL HYPERTENSION INDUSTRY STUDY

  • 4.1. Porter's Analysis
  • 4.2. Market Attractiveness Analysis
  • 4.3. Regulatory Framework Analysis

5. PULMONARY ARTERIAL HYPERTENSION MARKET LANDSCAPE

  • 5.1. Market Share Analysis

6. PULMONARY ARTERIAL HYPERTENSION MARKET - BY DRUG CLASS

  • 6.1. Overview
  • 6.2. Prostacyclin and Analogs
    • 6.2.1. Overview
    • 6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 6.3. Soluble Guanylyl Cyclase (SGC) Stimulators
    • 6.3.1. Overview
    • 6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 6.4. Endothelin receptor antagonist (ERA)
    • 6.4.1. Overview
    • 6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 6.5. Phosphodiesterase-5
    • 6.5.1. Overview
    • 6.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)

7. PULMONARY ARTERIAL HYPERTENSION MARKET- BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. Overview
    • 7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.2.3. U.S.
    • 7.2.3.1. Overview
    • 7.2.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.2.4. Canada
    • 7.2.4.1. Overview
    • 7.2.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 7.3. Europe
    • 7.3.1. Overview
    • 7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.3.3. France
    • 7.3.3.1. Overview
    • 7.3.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.3.4. Germany
    • 7.3.4.1. Overview
    • 7.3.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.3.5. Rest of Europe
    • 7.3.5.1. Overview
    • 7.3.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 7.4. Asia Pacific (APAC)
    • 7.4.1. Overview
    • 7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.4.3. China
    • 7.4.3.1. Overview
    • 7.4.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.4.4. India
    • 7.4.4.1. Overview
    • 7.4.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.4.5. Rest of APAC
    • 7.4.5.1. Overview
    • 7.4.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 7.5. Rest of the World
    • 7.5.1. Overview
    • 7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.5.3. Latin America
    • 7.5.3.1. Overview
    • 7.5.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.5.4. Middle East and Africa
    • 7.5.4.1. Overview
    • 7.5.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)

8. KEY VENDOR ANALYSIS

  • 8.1. Pfizer, Inc.
    • 8.1.1. Company Overview
    • 8.1.2. SWOT Analysis
    • 8.1.3. Key Developments
  • 8.2. GlaxoSmithKline
    • 8.2.1. Company Overview
    • 8.2.2. SWOT Analysis
    • 8.2.3. Key Developments
  • 8.3. Novartis
    • 8.3.1. Company Overview
    • 8.3.2. SWOT Analysis
    • 8.3.3. Key Developments
  • 8.4. Bayer
    • 8.4.1. Company Overview
    • 8.4.2. SWOT Analysis
    • 8.4.3. Key Developments
  • 8.5. Merck
    • 8.5.1. Company Overview
    • 8.5.2. SWOT Analysis
    • 8.5.3. Key Developments

Client can request additional company profiling as per specific requirements

9. 360 DEGREE ANALYSTVIEW

10. APPENDIX

  • 10.1. Research Methodology
  • 10.2. Abbreviations
  • 10.3. Disclaimer
  • 10.4. Contact Us
Back to Top
전화 문의
F A Q